30 studies found for:    Von Hippel-Lindau Disease (VHL)
Show Display Options
Rank Status Study
21 Recruiting Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders
Conditions: Hemangioblastoma;   Hereditary Neoplastic Syndrome;   Hippel Lindau Disease;   Neoplasm;   Renal Cell Carcinoma
Intervention:
22 Terminated
Has Results
Vandetanib to Treat Advanced Kidney Cancer
Condition: Advanced Clear Cell Renal Carcinoma
Intervention: Drug: vandetanib
23 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)
24 Completed
Has Results
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Biological: incomplete Freund's adjuvant;   Biological: von Hippel-Lindau peptide vaccine
25 Completed Metabolic Mapping to Measure Retinal Metabolism
Conditions: Macular Degeneration;   Diabetic Retinopathy;   Hippel-Landau Disease;   Retina[ME];   Mitochondria
Intervention: Procedure: Feasibility Study - Imaging System
26 Recruiting National Eye Institute Biorepository for Retinal Diseases
Conditions: Age-Related Macular Degeneration;   Diabetic Retinopathy;   Von Hippel-Lindau Syndrome;   Retinal Disease;   Retinal Vein Occlusion
Intervention:
27 Recruiting Diagnosis of Pheochromocytoma
Condition: Pheochromocytoma
Intervention:
28 Completed Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
Condition: Clear Cell Renal Cell Carcinoma
Interventions: Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
29 Recruiting pazopanib_NCRCC,Ph2 STUDY
Condition: Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
Intervention: Drug: pazopanib
30 Recruiting A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Cabozantinib (XL184);   Drug: Everolimus (Afinitor)

Show previous page of results Previous Page (1-20) Studies Shown (21-30) Next Page
Indicates status has not been verified in more than two years